Researchers at The University of Texas MD Anderson Cancer Center have identified a link between an enzyme tied to cancer formation and therapy resistance in patients with epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer (NSCLC). They believe two existing therapies may hold promise for clinical studies for this deadly and common lung cancer for which relapse often occurs within one year following treatment...
In his first interview since leaving public office in March, former U.S. Secretary of State Rex Tillerson spoke to CBS News' Bob Schieffer...
A follow-up analysis of patients enrolled in a Phase I/II multi-center trial for diffuse large B-cell lymphoma (DLBCL) reported 51 percent...
MD Anderson extends deepest sympathy to the family of former President George H.W. Bush. The institution mourns the loss of an extraordinary man who was not only an internationally respected bipartisan leader and humanitarian but also a devoted friend of the institution. He was a dedicated ambassador of the MD Anderson Cancer Center Board of Visitors (BOV) and an inspiration in our mission to end cancer. As we mark the end of an era,...
The University of Texas MD Anderson Cancer Center and the Houston Dynamo today announced plans to work together toward one goal: end cancer...
Two leaders in the field of melanoma treatment – a surgeon and an oncologist – from The University of Texas MD Anderson Cancer Center have...
Research on a new way of deploying the immune system against pancreatic cancer, an exceptionally lethal cancer that has so far resisted new...
The University of Texas MD Anderson Cancer Center applauds new actions announced today by the U.S. Food and Drug Administration (FDA) to limit...
A Phase I/II study, led by investigators at The University of Texas MD Anderson Cancer Center, reports an investigational drug called tagraxofusp...
A triple therapy combining two immune checkpoint inhibitors (ICPIs) with the standard-of-care chemotherapy, a hypomethylating agent called...